GlassScriptPhysician profile
Agnes H Han
NPI 1841268364
$4,422.27
in general payments reported to CMS, 2019-2025
31 companies · $692 in 2025
The $692 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $725 · 2020: $210 · 2021: $624 · 2022: $638 · 2023: $860 · 2024: $673 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,172 · Education: $53.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,172.36 |
| Education | $53.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,143.37 | 2019-2025 | |
| Pfizer INC. | $492.73 | 2019-2025 | |
| Madrigal Pharmaceuticals | $403.54 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $205.89 | 2019-2023 | Trulance |
| Regeneron Healthcare Solutions, INC. | $197.49 | 2022-2024 | Dupixent |
| Janssen Biotech, INC. | $189.51 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $167.93 | 2019-2023 | Dificid |
| Genzyme Corporation | $146.24 | 2022-2023 | |
| Gilead Sciences, INC. | $139.84 | 2019-2023 | |
| Allergan, INC. | $128.38 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $98.19 | 2019-2025 | Entyvio |
| Evoke Pharma, INC. | $97.12 | 2022-2023 | Gimoti |
| Qol Medical, LLC | $95.91 | 2021-2022 | |
| Celgene Corporation | $87.74 | 2021-2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $87.11 | 2024-2025 | Voquezna |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $84.03 | 2023-2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $73.54 | 2019-2023 | Linzess |
| Ipsen Biopharmaceuticals, INC | $70.47 | 2024-2025 | Iqirvo |
| Redhill Biopharma INC. | $66.53 | 2020-2021 | |
| Braintree Laboratories, INC. | $57.72 | 2024-2025 | Suflave, Sutab |
| Nestle Healthcare Nutrition INC. | $57.55 | 2021-2022 | |
| Lilly USA, LLC | $49.54 | 2025 | Omvoh |
| Daiichi Sankyo INC. | $48.66 | 2019 | |
| Ardelyx, INC. | $46.49 | 2023-2024 | Ibsrela |
| Ferring Pharmaceuticals INC. | $39.07 | 2019-2020 | |
| Sandoz INC. | $35.38 | 2023 | Hyrimoz |
| Intra-Sana Laboratories | $31.36 | 2021-2022 | |
| Olympus America INC. | $27.06 | 2021-2025 | Evis Exera III Colonovideoscope |
| Alexion Pharmaceuticals, INC. | $21.78 | 2019 | |
| Organon LLC | $19.61 | 2023 | Renflexis, Hadlima |
| Alfasigma USA, INC. | $12.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Agnes Han listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.